Matthew Galsky, MD
- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Urology
Dr. Galsky specializes in the care of patients with genitourinary malignancies (bladder, prostate, kidney, and testicular cancers). His research focuses on the development of novel treatments for these cancers and he has published extensively in this area. He serves as Director of Genitourinary Medical Oncology at the Tisch Cancer Institute.
- Bladder Cancer
- Kidney Cancer
- Primary Pulmonary Hypertension
- Prostate Cancer
- Testicular Tumors
- Urologic Cancers
Residency, Internal Medicine, Beth Israel Deaconess Medical Center- Harvard Medical School
Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center
American Society of Clinical Oncology Merit Award
Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)
Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy)
Alpha Omega Alpha Honor Society
- A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel,
The purpose of this study is to:
- Test the safety of the research study drug, pembrolizumab (also called MK-3475)
- Test the effectiveness of the research study drug pembrolizumab compared to paclitaxel or docetaxel or vinflunine for recurrent/progres...
- A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer
The purpose of this study is to look at the effects, good or bad, of an experimental drug called MPDL3280A on you and your bladder cancer. An experimental dr...
- A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will al...
- A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer
The purpose of this study is to compare the good and bad effects of pembrolizumab to a placebo in people with metastatic or unresectable bladder cancer that responded after initial chemotherapy. in this study, you will get either pembrolizumab or placebo. A placebo...
- Phase II Trial of Gemcitabine, Cisplatin, plus Ipilimumab as First-line Treatment for Patients with Metastatic Urothelial Carcinoma
- A Pilot Study of Abiraterone Acetate in African American/Black Patients with Castration Resistant Prostate Cancer
The purpose of this study is to evaluate the effects of abiraterone acetate on prostate cancer in African American/Black men and will determine if difference in genes measured in the blood impact the likelihood of prostate cancer to respond to treatment with abiraterone acetat...
- A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus
The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will all...